Our Parkinson's Place: Ministry OKs Peptron’s P2 clinical trial of Parkinson’s disease treatment

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Monday, February 18, 2019

Ministry OKs Peptron’s P2 clinical trial of Parkinson’s disease treatment

February 18, 2019 Lee Han-soo

Peptron said Monday that the Ministry of Food and Drug Safety has approved its revised phase 2 clinical trial plans of PT320, a Parkinson’s disease treatment candidate.

PT320 is a GLP-1 receptor activator, a type of incretin hormone, which is likely to become a therapeutic drug for Parkinson's disease as it has shown efficacy against central nervous system diseases.

Under the changed plan, the company will produce the candidate at its Osong plant, which received GMP approval from the ministry on Thursday. Peptron intends to develop new drugs from its production facilities for the clinical trial and final commercialization of the treatment.

The company expects to complete the trial by 2020 and will evaluate the efficacy and safety of PT320 for symptom improvement and Parkinson's disease inhibition in patients with early Parkinson's disease at the Seoul National University Hospital and Asan Medical Center.

To increase the chance of success, the company has recruited Professor Choi Do-seob of the Mayo Clinic, to participate in the clinical trial design.

“With Professor Choi’s participation, the clinical level has been improved to global standards, greatly enhancing the possibility of success in drug development,” a company official said.

The company expects that Professor Choi will play a key role in analyzing clinical outcomes, publishing papers and presenting the data using his collaborative research network consisting of leading experts from the U.S. National Institutes of Health, as well as close links with domestic clinical staff, the official added.

corea022@docdocdoc.co.kr

http://www.koreabiomed.com/news/articleView.html?idxno=5146